<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Naftifine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Naftifine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Naftifine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10887" href="/d/html/10887.html" rel="external">see "Naftifine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F199234"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Naftin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F199249"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antifungal Agent, Topical</li></ul></div>
<div class="block doa drugH1Div" id="F199235"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15c0a5bc-b04b-4bce-808a-eba28afcd673">Tinea infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea corporis/tinea cruris:</i>
<b>Topical: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Cream 1% and 2%, gel 1%: Apply to affected and surrounding area(s) once daily (cream) or twice daily (gel) until clinical resolution, typically 1 to 4 weeks; resolution may be faster with 2% cream (Goldstein 2021; Parish 2011a; van Zuuren 2015; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea pedis (labeled use)/tinea manuum (off-label use):</i>
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Cream 1% and 2%, gel 1% and 2%: Apply to affected and surrounding area(s) once daily (cream and 2% gel) or twice daily (1% gel) until 1 week after clinical resolution, typically for 2 to 4 weeks total; resolution may be faster with 2% formulations (Goldstein 2021; Parish 2011b; Stein Gold 2013; Weinstein 2002; manufacturer’s labeling).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990131"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987446"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F199236"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F26320837"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="91308f4e-1873-43db-bd46-e267c1c56c76">Tinea corporis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea corporis:</b> Children ≥2 years and Adolescents: Topical Cream 2%: Refer to adult dosing.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b2fc666-8163-4230-9429-13cd730abee9">Tinea cruris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea cruris:</b> Children ≥12 years and Adolescents: Topical: Cream 2%: Refer to adult dosing.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1376e31-faad-4461-817a-14499006c2ba">Tinea pedis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea pedis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Topical: Gel 2%: Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Topical: Cream 2%: Refer to adult dosing.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51159491"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51159492"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F199218"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Burning sensation of skin (5% to 6%), xeroderma (3%), skin irritation (2%), erythema (≤2%), pruritus (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Local: Application site reaction (2%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, crusted skin, dizziness, headache, inflammation, leukopenia, maceration, pain, rash, serous drainage, skin blister, skin tenderness, swelling of skin</p></div>
<div class="block coi drugH1Div" id="F199227"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to naftifine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F199215"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Irritation: Discontinue if sensitivity or irritation occurs and institute appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For topical use only; not intended for oral, ophthalmic, or vaginal use. Avoid use of occlusive dressings and contact with eyes, nose, mouth, or mucous membranes.</p></div>
<div class="block foc drugH1Div" id="F199223"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naftin: 2% (45 g [DSC], 60 g [DSC]) [contains benzyl alcohol, cetyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (60 g, 90 g); 2% (45 g, 60 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naftin: 1% (40 g, 60 g, 90 g) [contains alcohol, usp, edetate (edta) disodium, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naftin: 2% (45 g, 60 g) [contains alcohol, usp, benzyl alcohol, edetate (edta) disodium, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (40 g [DSC], 60 g [DSC], 90 g [DSC]); 2% (45 g, 60 g)</p></div>
<div class="block geq drugH1Div" id="F199211"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F199228"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Naftifine HCl External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per gram): $6.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per gram): $8.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Naftifine HCl External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per gram): $11.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Naftin External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per gram): $9.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per gram): $12.93</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F14181999"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Topical:</b> For topical use only; avoid nasal, ophthalmic, oral or intravaginal use. Wash hands before and after use. Apply to clean, dry skin. Avoid occlusive dressings.</p></div>
<div class="block admp drugH1Div" id="F52744166"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: Cream 2%, Gel 2%: For topical use only; avoid nasal, ophthalmic, oral, or intravaginal use. Wash hands before and after use. Apply to clean, dry skin. Apply to the affected area(s) and a <sup>1</sup>/<sub>2</sub>-inch margin of healthy surrounding tissue. Avoid occlusive dressings. Discontinue treatment if irritation or sensitivity develops.</p></div>
<div class="block use drugH1Div" id="F199224"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea infections:</b> Cream 1% and 2%, Gel 1%: Topical treatment of tinea cruris (jock itch), tinea corporis (ringworm), and tinea pedis (athlete's foot).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea pedis:</b> Gel 2%: Topical treatment of tinea pedis (athlete's foot).</p></div>
<div class="block off-label drugH1Div" id="F56324192"><span class="drugH1">Use: Off-Label: Adult</span><p>Tinea manuum</p></div>
<div class="block cyt drugH1Div" id="F13299736"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F199219"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F5204542"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Naftifine is absorbed systemically (4% to 6%) following topical administration. Application over a limited area is considered likely acceptable during pregnancy (Patel 2017).</p></div>
<div class="block brc drugH1Div" id="F20616399"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if naftifine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F14182001"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Culture and KOH exam; re-evaluate if no improvement after 4 weeks of therapy</p></div>
<div class="block pha drugH1Div" id="F199214"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Synthetic, broad-spectrum antifungal agent in the allylamine class; appears to have both fungistatic and fungicidal activity. Exhibits antifungal activity by selectively inhibiting the enzyme squalene epoxidase in a dose-dependent manner which results in a reduced synthesis of ergosterol, the primary sterol within the fungal membrane, and increased squalene in cells.</p></div>
<div class="block phk drugH1Div" id="F199226"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Systemic: Cream: 6%; Gel: 4% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 2 to 3 days </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine and feces (as unchanged drug and/or metabolites) </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F199229"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Xin xin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Micosona</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Exoderil | Lonaderm</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Exodril</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Naftifast</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Suadian</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Baretoc | Exoderil | Il yang naftifine hcl | Nafgen | Nafnal | Naftin | Nafzol | Naphri | Ramidipine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Exoderil | Fetimin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Exoderil | Fetimin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Naftifine HCL | Naftin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Exoderil | Exostat | Mycoderil | Naftifine | Naftoderil</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Exoderil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dermifin | Exelderm | Exoderil | Funderyl | Nafderilex | Naxoder</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ancent | Anzumei | Chizocin | Decent | Exoderil | Genaf | Jia Mei | Kafutinea | Nafdin | Naftifine | Natifim | Tifin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Eczo tifin | Estezifin | Exik | Exo-derm | Exoderil | Exolik | Naftifin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Goldstein.1">
<a name="Goldstein.1"></a>Goldstein AO, Goldstein BG. Dermatophyte (tinea) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18478357">
<a name="18478357"></a>Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. <i>Mycopathologia</i>. 2008;166(5-6):353-367. doi:10.1007/s11046-008-9109-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naftifine-drug-information/abstract-text/18478357/pubmed" id="18478357" target="_blank">18478357</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Naftifine hydrochloride 2% cream [prescribing information]. Florham Park, NJ: Xiromed LLC; September 2020.</div>
</li>
<li>
<div class="reference">
                  Naftin 1% cream (naftifine hydrochloride) [prescribing information]. Roswell, GA: Sebela Pharmaceuticals Inc; April 2018.</div>
</li>
<li>
<div class="reference">
                  Naftin 2% cream (naftifine hydrochloride) [prescribing information]. Roswell, GA: Sebela Pharmaceuticals Inc; April 2018.</div>
</li>
<li>
<div class="reference">
                  Naftin 1% gel (naftifine hydrochloride) [prescribing information]. Roswell, GA: Sebela Pharmaceuticals Inc; May 2018.</div>
</li>
<li>
<div class="reference">
                  Naftin 2% gel (naftifine hydrochloride) [prescribing information]. Roswell, GA: Sebela Pharmaceuticals Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21968664">
<a name="21968664"></a>Parish LC, Parish JL, Routh HB, et al. A Double-Blind, Randomized, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Naftifine 2% Cream in Tinea cruris. <i>J Drugs Dermatol.</i> 2011a;20(10):1142-1147.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naftifine-drug-information/abstract-text/21968664/pubmed" id="21968664" target="_blank">21968664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052309">
<a name="22052309"></a>Parish LC, Parish JL, Routh HB, et al. A Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of Naftifine 2% Cream in the Treatment of Tinea pedis. <i>J Drugs Dermatol. </i>2011b;10(11):1282-1288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naftifine-drug-information/abstract-text/22052309/pubmed" id="22052309" target="_blank">22052309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28449377">
<a name="28449377"></a>Patel VM, Schwartz RA, Lambert WC. Topical antiviral and antifungal medications in pregnancy: a review of safety profiles. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(9):1440-1446. doi:10.1111/jdv.14297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naftifine-drug-information/abstract-text/28449377/pubmed" id="28449377" target="_blank">28449377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23986165">
<a name="23986165"></a>Stein Gold LF, Parish LC, Vlahovic T, et al. Efficacy and safety of naftifine HCl gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials. <i>J Drugs Dermatol</i>. 2013;12(8):911-918.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naftifine-drug-information/abstract-text/23986165/pubmed" id="23986165" target="_blank">23986165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25294700">
<a name="25294700"></a>van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. <i>Br J Dermatol</i>. 2015;172(3):616-641. doi:10.1111/bjd.13441<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naftifine-drug-information/abstract-text/25294700/pubmed" id="25294700" target="_blank">25294700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12046779">
<a name="12046779"></a>Weinstein A, Berman B. Topical treatment of common superficial tinea infections. <i>Am Fam Physician</i>. 2002;65(10):2095-2102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naftifine-drug-information/abstract-text/12046779/pubmed" id="12046779" target="_blank">12046779</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9675 Version 236.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
